Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genmab and GSK receive EU authorization for Arzerra


Thursday, 3 Jul 2014 09:15am EDT 

Genmab A/S:Announces together with GlaxoSmithKline plc that European Commission (EC) has granted marketing authorization for new indication for use of Arzerra (ofatumumab), human monoclonal antibody against CD20.Authorization granted for Arzerra in combination with chlorambucil or bendamustine for treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy.Ofatumumab is being developed under co-development and collaboration agreement between Genmab and GSK. 

Company Quote

220.0
4.3 +1.99%
8:46am EDT